We participated in the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
We, Stella Pharma, participated in the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from 30th May to 3rd June in Chicago, Illinois, USA.
At the poster session on May 31st, Dr. Shin-Ichi Miyatake of Osaka Medical and Pharmaceutical University (coordinating investigator of the trial) presented a summary of the primary analysis results of the Phase II investigator-initiated randomized controlled trial*1 of BNCT*2 (Boron Neutron Capture Therapy) on recurrent high-grade meningioma*3.
On the day of the presentation, the Abstract published in advance raised great interest, and many physicians, cancer research institutes, and pharmaceutical company representatives from US, Europe and Asia visited the booth and engaged in a lively exchange of opinions.
Astonishment was raised regarding the progression-free survival (PFS)*4 and higher response rate in the trial compared to the control group, while the prognosis of recurrent high-grade meningioma is extremely poor with existing treatments. extremely poor with existing treatments.
ASCO is the world’s largest oncology conference with more than 40,000 participants each year. Exhibition booths, poster sessions, displays of patient support groups and numerous lectures are organized for international researchers and medical professionals to share the knowledge about the latest cancer treatments and promote networking.
We strive to enlarge the possibilities for cancer treatment and contribute to the realization of better medical care.
*1 Randomized controlled trial
In a randomized controlled trial, the participants are divided at random into at least two groups. One group is treated with the conventional treatment and the other group is treated with the new therapy, and the effects of the treatments are verified by observing and comparing the health conditions of the subjects after the treatment.
*2 BNCT (Boron Neutron Capture Therapy)
Boron Neutron Capture Therapy is one sort of radiation therapy where a reaction between a boron containing drug and thermal neutrons occurs. As new cancer treatment, the damage caused to the body is small and the effectiveness is expected to be high.
*3 Recurrent high-grade meningioma
Meningiomas are categorized into one type of brain tumors that develops in one of the inner layers of the meninges, which are thin layers of tissue that protect the brain and spinal cord. The most common kind of meningioma is benign (WHO grade 1), but if highly malignant (WHO grade 2 or 3), it can deeply invade the brain, cerebrovascular vessels, the skull and recur repeatedly. If recurrent, surgery or radiotherapy (external x-ray radiation) are applicable, but the results are limited and there is no effective treatment developed yet.
*4 Progression-free survival
Progression-free survival is one indicator to measure the effectiveness of a cancer treatment. It shows the period after treatment until progression or recurrence of cancer, or the time until the death of the patient.
About Stella Pharma Corporation
In accordance with our company philosophy “For a precious and irreplaceable life” we strive to “shed a new light on global healthcare” and our management guidelines are based on this principle.
From our beginning we have been working on research and development of BNCT boron drugs in order to realize BNCT for practical use as new treatment option for cancer patients.
Website: https://stella-pharma.co.jp/en/
Contact: Stella Pharma Corporation, General Affairs Department Contact form: https://stella-pharma.co.jp/en/otioawase/
